Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247739 | 1.00 | KMT2A (0.47) | KMT2AMAPTMEN1LMNACYP2C9 | |
| SCHEMBL10324405 | 0.86 | SMN1; SMN2 (0.63) | KMT2AMAPTMEN1LMNACYP2C9 | |
| SCHEMBL10324404 | 0.86 | SMN1; SMN2 (0.63) | KMT2AMAPTMEN1LMNACYP2C9 | |
| SCHEMBL247857 | 0.86 | ALDH1A1 (0.55) | KMT2AMAPTMEN1LMNACYP2C9 | |
| SCHEMBL247856 | 0.86 | ALDH1A1 (0.55) | KMT2AMAPTMEN1LMNACYP2C9 | |
| SCHEMBL23269630 | 0.85 | ALDH1A1 (0.58) | KMT2AMEN1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL28485887 | 0.77 | GLA (0.50) | KMT2AMAPTMEN1LMNASMN1; SMN2 | |
| SCHEMBL16109884 | 0.74 | MAPT (0.51) | KMT2AMAPTMEN1LMNACYP2C9 | |
| SCHEMBL16109883 | 0.74 | MAPT (0.51) | KMT2AMAPTMEN1LMNACYP2C9 | |
| SCHEMBL246651 | 0.73 | KMT2A (0.40) | KMT2AMAPTMEN1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| CN-107021951-B | sGC stimulators | 赛克里翁治疗有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-20190345130-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10189809-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170305878-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3173407-A1 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2588465-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20140323448-A1 | sGC STIMULATORS | Ironwood Pharmaceuticals Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748442-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2588465-A1 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120184516-A1 | sGC Stimulators | CYCLERION THERAPEUTICS, INC. | 2012-07-19 | — | — | US | disclosed |
| WO-2012003405-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323448-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MAPT 4837/4885MEN1 3461/4885 |
| US-20120184516-A1 | sGC Stimulators | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MAPT 4837/4885MEN1 3461/4885 |
| US-20170305878-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MAPT 4837/4885MEN1 3461/4885 |
| US-10189809-B2 | SGC stimulators | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MAPT 4837/4885MEN1 3461/4885 |
| US-20190345130-A1 | SGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MAPT 4837/4885MEN1 3461/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KMT2A 4149/4885MAPT 4837/4885MEN1 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.